Your baby’s first steps to a healthy life

What is Newborn Metabolic Screening?

It is a screening for every newborn for many harmful or potentially fatal metabolic disorders (also known as inborn errors of metabolism, or IEMs for short) that are not apparent at birth. An inborn error of metabolism (IEM) is a rare genetic disorder where the affected baby lacks certain enzymes that maintain normal bodily metabolic function, causing the build-up of toxic substances or deficiency of critical substances required for development.

Why Choose Metascreen™

Screening of more than 100 metabolic disorders is now possible with Metascreen™, the most comprehensive non-invasive newborn metabolic screening in Indonesia.

Age Expanded Screening

Screen your baby from 48 hours (2 days) after birth, up until 6 months of age. Ideally, your baby should be screened between 2 to 7 days after birth.

Simple and Painless Urine Test

Your baby’s urine can be easily collected by inserting filter paper into the diaper without causing any harm or discomfort to your baby.

Most Comprehensive Coverage in Indonesia

More than 100 life-threatening metabolic disorders can be detected from a single urine test.

Timely Screening Report

The results will be available within 14 working days upon receipt of urine sample at StemLife laboratory to enable early treatment, if necessary.

Real Stories

Battling with Canavan Disease

Early detection for effective disease management

Corrigan, now 7, enjoys his time splashing in the inflatable pool, something his parents never knew possible. As soon after birth, he was diagnosed with Citrullinemia.

Appearing normal and healthy at birth, Corrigan’s ammonia levels crept up shortly after birth, with several vomiting episodes followed by progressive lack for energy (lethargy) which set off the alarm that something was not right. A random guess and confirmation through a newborn screening test, Corrigan’s diagnosis of Citrullinemia type 1 allowed for immediate treatment at John Hopkins University. To this day, though Corrigan suffers from periodic stays in hospital due to hyper-ammonia or weaken immune system, he benefits daily from medicine, management and restriction of diet through arginine supplementation.

Did you know: CIT type I affects about one in 57,000 people worldwide, and CIT type 2 can affect one out of 20,000 people in Asia.

About Us

MetascreenTM is a trademark or registered trademark of Cordlife Group Limited, a Singapore Exchange Mainboard listed company. The screening test offered under the brand is conducted by Hong Kong Screening Centre, a CAP-accredited laboratory committed to providing early and accurate detection of metabolic disorders in newborn babies. Hong Kong Screening Centre has a quality management system in place to ensure maximum accuracy of screening results. As with any laboratory tests, false positive or false negative results cannot be completely eliminated due to various reasons including but not limited to age of patient at the time of specimen collection, patient’s health status, specimen quality and other variables. Hence, the risk of a disorder should never be precluded solely on the basis of screening. Signs or symptoms observed should be followed up immediately by a professional healthcare provider.